Tony Berberabe, MPH

With the emergence of the novel treatments abiraterone acetate (Zytiga) and enzalutamide (Xtandi), urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer patients.

Thomas E. Keane, MD, ChB, discussed combination approaches in treatment-resistant mCRPC at the 2015 LUGPA Annual Meeting.

Independent urology practices are at a crossroads as they face substantial Medicare payment change, shifts in physician employment and autonomy, and cutting edge developments in clinical care.

Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic anti–CTLA-4 immunotherapy, ipilimumab.

The FDA has issued a de novo clearance for a minimally invasive high-intensity focused ultrasound for prostate tissue ablation called Sonablate 450 and marketed by SonaCare Medical, LLC.

Patients with renal cell carcinoma have better outcomes when undergoing nephron-sparing surgery rather than radical nephrectomy.

With the advancement of radium-223 comes questions and controversy regarding optimal treatment sequencing, combination therapy, and appropriate patient selection.

In the urologic oncology field, urologists can play an important role in successful comprehensive care by incorporating palliative care in their treatment regimens.

Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.

New diagnoses of prostate cancer cases declined nearly 30% after the United States Preventive Services Task Force recommended against routine prostate-specific antigen screening for men.

Urologists who are in solo practice or not affiliated with a medical school may overuse primary gonadotropin-releasing hormone for men with localized prostate cancer.

Men with intermediate- or high-risk prostate cancer experienced higher survival rates when given increased radiation doses than men with low-risk disease.

Patients who were taking statins while also undergoing androgen deprivation therapy may experience a reduction in all-cause and prostate cancer-specific deaths.

Charles J. Ryan, MD, discusses the final survival data for pre-chemotherapy use of abiraterone from the COUGAR-AA-302 study, which demonstrated a median of 35 months for men with castration resistant prostate cancer.

There are many processes for a urology practice to consider when partnering with a specialty pharmacy, including time and capital investments.

Using an allograft made up of dehydrated human amnion/chorion membrane wrapped around the neurovascular bundle (NVB) during nerve-sparing robot-assisted radical prostatectomy improved continence and potency postsurgery, according to results of a small study.

Interest is high among urologists and medical oncologists with "the explosion of checkpoint blockade inhibition studies" that initially made inroads in melanoma and non-small cell lung cancer, but is also gaining traction in bladder cancer.

Two urine biomarkers, aquaporin 1 and perilipin 2, could be the key to the development of a simple urine test that leads to the detection of asymptomatic, early-stage kidney cancer.

Treatment with an adjuvant combination of docetaxel, androgen deprivation therapy (ADT), and radiation therapy (RT) improved 4-year overall survival rates in patients with high-risk localized prostate cancer, when compared with ADT plus RT alone.

After weeks of deliberations, the final votes have been cast and the winners of the 2015 Giants of Cancer Care® can now be revealed.

The growing use of genetic biomarker tests to screen, monitor, diagnose, and treat patients with cancer has the potential to improve outcomes and reduce costs, but payment systems for covering and reimbursing for these tests have fallen behind the times.

The combination of multiparametric MRI with a fusion-guided biopsy (MRI plus ultrasound) was more effective at detecting aggressive prostate cancer compared with either procedure alone.

Sexual function scores were better for patients who had a robotic compared with open surgery for prostate cancer; however, comparative results for urinary function were not conclusive.

Since the USPSTF guideline on PSA screening the overall rate of PSA testing decreased by 50% among primary care physicians at Oregon Health & Science University.

As the AS strategy gains a foothold among urologists both here in the US and around the world, a study presented at the 110th Annual Scientific Meeting of the American Urological Association suggests that among men in the US, very few are following the stringent protocol for AS that is recommended by major academic institutions.

The role of androgen receptor variant-7 in patients with early stage prostate cancer is not well characterized but data presented at the 2015 American Urological Association (AUA) Meeting is bringing the discussion into focus.

Treatment with olaparib demonstrated a durable overall response rate of 87.5% in a biomarker-defined subgroup of men with pretreated sporadic metastatic castration-resistant prostate cancer in a phase II multi-step adaptive trial.

Topline results announced today from the phase III Swedish trial 10TASQ10 demonstrated that tasquinimod failed to extend overall survival in men with metastatic castrate-resistant prostate cancer.

Treatment with enzalutamide reduced the risk of progression by 76% compared with bicalutamide in men with castration-resistant prostate cancer.

Older, single white males with advanced bladder cancer have the highest suicide risk among those with other cancers of the male genitals and urinary system, researchers report.